Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.46 |
| ▸ | RECQL | P46063 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | F12 | P00748 | 1/20 | 0.46 |
| ▸ | F7 | P08709 | 1/20 | 0.46 |
| ▸ | F3 | P13726 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2185852 | 0.75 | AKT1 (0.59) | AKT1TSHRBLMRECQLTDP1 | |
| SCHEMBL18189195 | 0.74 | AKT1 (0.52) | AKT1TSHRBLMRECQLTDP1 | |
| SCHEMBL1403013 | 0.74 | TDP1 (0.54) | AKT1TSHRBLMRECQLTDP1 | |
| Benzamide SCHEMBL8991968 | 0.73 | PARP1 (0.73) | AKT1TSHRBLMRECQLTDP1 | |
| Benzoic Acid SCHEMBL3718190 | 0.73 | TSHR (0.64) | AKT1TSHRBLMRECQLTDP1 | |
| Benzophenone SCHEMBL1884581 | 0.73 | ALDH1A1 (0.64) | AKT1TSHRBLMRECQLTDP1 | |
| Benzoic Acid SCHEMBL26696911 | 0.73 | TSHR (0.64) | AKT1TSHRBLMRECQLTDP1 | |
| Acrylamide SCHEMBL28673779 | 0.73 | AKT1 (0.58) | AKT1TSHRBLMRECQLTDP1 | |
| SCHEMBL23328518 | 0.72 | AKT1 (0.56) | AKT1TSHRBLMRECQLTDP1 | |
| SCHEMBL630088 | 0.72 | AKT1 (0.56) | AKT1TSHRBLMRECQLTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103755743-B | Method for producing a ruthenium complex | 高砂香料工业株式会社 | 2017-05-10 | — | — | CN | claimed |
| CN-101676294-B | Method for producing ruthenium complex | TAKASAGO PERFUMERY CO LTD | 2014-06-18 | — | — | CN | claimed |
| CN-103755743-A | Method for producing a ruthenium complex | TAKASAGO PERFUMERY CO LTD | 2014-04-30 | — | — | CN | claimed |
| EP-2166014-B1 | Method for producing a ruthenium complex | TAKASAGO PERFUMERY CO LTD (JP) | 2012-11-14 | — | — | EP | claimed |
| US-7964744-B2 | Method for producing a ruthenium complex | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2011-06-21 | — | — | US | claimed |
| EP-2275429-A2 | Method for producing a ruthenium complex | Takasago International Corporation (JP) | 2011-01-19 | — | — | EP | claimed |
| US-20100076210-A1 | METHOD FOR PRODUCING A RUTHENIUM COMPLEX | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-03-25 | — | — | US | claimed |
| EP-2166014-A2 | Method for producing a ruthenium complex | Takasago International Corporation (JP) | 2010-03-24 | — | — | EP | claimed |
| CN-101676294-A | Method for producing ruthenium complex | TAKASAGO PERFUMERY CO LTD | 2010-03-24 | — | — | CN | claimed |
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | TRANSMIT GESELLSCHAFT FUR TECHNOLOGIETRANSFER MBH (DE) | 2005-10-27 | — | — | US | claimed |
| EP-1503990-A1 | ACTIVE SUBSTANCES FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF DISEASES IN WHICH ABNORMAL PROTEIN STRUCTURES OCCUR | Transmit Gesellschaft für Technologietransfer mbH (DE) | 2005-02-09 | — | — | EP | claimed |
| WO-2003095429-A1 | ACTIVE SUBSTANCES FOR THE TREATMENT, DIAGNOSIS AND PROPHYLAXIS OF DISEASES IN WHICH ABNORMAL PROTEIN STRUCTURES OCCUR | TransMIT Gesellschaft für Technologietransfer mbH (DE) | 2003-11-20 | — | — | WO | claimed |
| US-4962230-A | RUTHENIUM-OPTICALLY ACTIVE PHOSPHINE COMPLEX HYDROGENATION CATALYST | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1990-10-09 | — | — | US | claimed |
| US-20230348398-A1 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2023-11-02 | — | — | US | disclosed |
| CN-103755743-B | Method for producing a ruthenium complex | 高砂香料工业株式会社 | 2017-05-10 | — | — | CN | disclosed |
| CN-103755743-B | Method for producing a ruthenium complex | 高砂香料工业株式会社 | 2017-05-10 | — | — | CN | disclosed |
| EP-0196174-B1 | MEANS FOR SEQUENTIAL SOLID PHASE ORGANIC SYNTHESIS AND METHODS USING THE SAME | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1990-01-17 | — | — | EP | disclosed |
| EP-0257486-A1 | Modified polyphenylene ether resins having improved processability and oxidative stability | GENERAL ELECTRIC COMPANY (US) | 1988-03-02 | — | — | EP | disclosed |
| US-4631211-A | REACTIVE PARTICLES ENCLOSED IN WATER AND SOLVENT-INSOLUBLE MESH CONTAINER; PEPTIDE SYNTHESIS | SCRIPPS CLINIC & RESEARCH FOUNDATION (US) | 1986-12-23 | — | — | US | disclosed |
| EP-0196174-A2 | Means for sequential solid phase organic synthesis and methods using the same | SCRIPPS CLINIC AND RESEARCH FOUNDATION (US) | 1986-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348398-A1 | Benzimidazole derivatives | HRH4, H1-4, CYP3A4 | AKT1 4161/4885TSHR 388/4885BLM 1614/4885 |
| US-20100076210-A1 | METHOD FOR PRODUCING A RUTHENIUM COMPLEX | OGFRL1, OPRM1, OLA1 | AKT1 2761/4885TSHR 1364/4885BLM 4284/4885 |
| US-20050239808-A1 | Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur | PRNP, APP, MAPT | AKT1 3368/4885TSHR 4200/4885BLM 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.